139 related articles for article (PubMed ID: 12746839)
1. ErbB1 and prostate cancer: ErbB1 activity is essential for androgen-induced proliferation and protection from the apoptotic effects of LY294002.
Tørring N; Dagnaes-Hansen F; Sørensen BS; Nexø E; Hynes NE
Prostate; 2003 Jul; 56(2):142-9. PubMed ID: 12746839
[TBL] [Abstract][Full Text] [Related]
2. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.
Motoyama AB; Hynes NE; Lane HA
Cancer Res; 2002 Jun; 62(11):3151-8. PubMed ID: 12036928
[TBL] [Abstract][Full Text] [Related]
3. The phosphatidylinositol 3'-kinase pathway is a dominant growth factor-activated cell survival pathway in LNCaP human prostate carcinoma cells.
Lin J; Adam RM; Santiestevan E; Freeman MR
Cancer Res; 1999 Jun; 59(12):2891-7. PubMed ID: 10383151
[TBL] [Abstract][Full Text] [Related]
4. Growth inhibitory effects of the dual ErbB1/ErbB2 tyrosine kinase inhibitor PKI-166 on human prostate cancer xenografts.
Mellinghoff IK; Tran C; Sawyers CL
Cancer Res; 2002 Sep; 62(18):5254-9. PubMed ID: 12234993
[TBL] [Abstract][Full Text] [Related]
5. Long-term androgen-ablation causes increased resistance to PI3K/Akt pathway inhibition in prostate cancer cells.
Pfeil K; Eder IE; Putz T; Ramoner R; Culig Z; Ueberall F; Bartsch G; Klocker H
Prostate; 2004 Feb; 58(3):259-68. PubMed ID: 14743465
[TBL] [Abstract][Full Text] [Related]
6. EGF promotes neuroendocrine-like differentiation of prostate cancer cells in the presence of LY294002 through increased ErbB2 expression independent of the phosphatidylinositol 3-kinase-AKT pathway.
Cortés MA; Cariaga-Martinez AE; Lobo MV; Martín Orozco RM; Motiño O; Rodríguez-Ubreva FJ; Angulo J; López-Ruiz P; Colás B
Carcinogenesis; 2012 Jun; 33(6):1169-77. PubMed ID: 22461520
[TBL] [Abstract][Full Text] [Related]
7. Androgens stimulate hypoxia-inducible factor 1 activation via autocrine loop of tyrosine kinase receptor/phosphatidylinositol 3'-kinase/protein kinase B in prostate cancer cells.
Mabjeesh NJ; Willard MT; Frederickson CE; Zhong H; Simons JW
Clin Cancer Res; 2003 Jul; 9(7):2416-25. PubMed ID: 12855613
[TBL] [Abstract][Full Text] [Related]
8. Role of PI3K signaling in survival and progression of LNCaP prostate cancer cells to the androgen refractory state.
Murillo H; Huang H; Schmidt LJ; Smith DI; Tindall DJ
Endocrinology; 2001 Nov; 142(11):4795-805. PubMed ID: 11606446
[TBL] [Abstract][Full Text] [Related]
9. Neuregulin promotes autophagic cell death of prostate cancer cells.
Tal-Or P; Di-Segni A; Lupowitz Z; Pinkas-Kramarski R
Prostate; 2003 May; 55(2):147-57. PubMed ID: 12661040
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of insulin-like growth factor binding protein-5 helps accelerate progression to androgen-independence in the human prostate LNCaP tumor model through activation of phosphatidylinositol 3'-kinase pathway.
Miyake H; Nelson C; Rennie PS; Gleave ME
Endocrinology; 2000 Jun; 141(6):2257-65. PubMed ID: 10830316
[TBL] [Abstract][Full Text] [Related]
11. EGFR signaling pathway negatively regulates PSA expression and secretion via the PI3K-Akt pathway in LNCaP prostate cancer cells.
Hakariya T; Shida Y; Sakai H; Kanetake H; Igawa T
Biochem Biophys Res Commun; 2006 Mar; 342(1):92-100. PubMed ID: 16472761
[TBL] [Abstract][Full Text] [Related]
12. Progression of LNCaP prostate tumor cells during androgen deprivation: hormone-independent growth, repression of proliferation by androgen, and role for p27Kip1 in androgen-induced cell cycle arrest.
Kokontis JM; Hay N; Liao S
Mol Endocrinol; 1998 Jul; 12(7):941-53. PubMed ID: 9658399
[TBL] [Abstract][Full Text] [Related]
13. FOXO3a mediates the androgen-dependent regulation of FLIP and contributes to TRAIL-induced apoptosis of LNCaP cells.
Cornforth AN; Davis JS; Khanifar E; Nastiuk KL; Krolewski JJ
Oncogene; 2008 Jul; 27(32):4422-33. PubMed ID: 18391984
[TBL] [Abstract][Full Text] [Related]
14. Signal transduction pathways in androgen-dependent and -independent prostate cancer cell proliferation.
Ghosh PM; Malik SN; Bedolla RG; Wang Y; Mikhailova M; Prihoda TJ; Troyer DA; Kreisberg JI
Endocr Relat Cancer; 2005 Mar; 12(1):119-34. PubMed ID: 15788644
[TBL] [Abstract][Full Text] [Related]
15. [Androgen regulation of secreted growth factors in prostate carcinoma cell and tumor lines].
Kellner U; Wagner B; Otto U; Voigt KD; Dietel M; Knabbe C
Verh Dtsch Ges Pathol; 1993; 77():124-8. PubMed ID: 7511269
[TBL] [Abstract][Full Text] [Related]
16. Melatonin and prostate cancer cell proliferation: interplay with castration, epidermal growth factor, and androgen sensitivity.
Siu SW; Lau KW; Tam PC; Shiu SY
Prostate; 2002 Jul; 52(2):106-22. PubMed ID: 12111702
[TBL] [Abstract][Full Text] [Related]
17. Tumor necrosis factor alpha induces BID cleavage and bypasses antiapoptotic signals in prostate cancer LNCaP cells.
Kulik G; Carson JP; Vomastek T; Overman K; Gooch BD; Srinivasula S; Alnemri E; Nunez G; Weber MJ
Cancer Res; 2001 Mar; 61(6):2713-9. PubMed ID: 11289152
[TBL] [Abstract][Full Text] [Related]
18. A flavonoid antioxidant, silymarin, inhibits activation of erbB1 signaling and induces cyclin-dependent kinase inhibitors, G1 arrest, and anticarcinogenic effects in human prostate carcinoma DU145 cells.
Zi X; Grasso AW; Kung HJ; Agarwal R
Cancer Res; 1998 May; 58(9):1920-9. PubMed ID: 9581834
[TBL] [Abstract][Full Text] [Related]
19. Dutasteride, the dual 5alpha-reductase inhibitor, inhibits androgen action and promotes cell death in the LNCaP prostate cancer cell line.
Lazier CB; Thomas LN; Douglas RC; Vessey JP; Rittmaster RS
Prostate; 2004 Feb; 58(2):130-44. PubMed ID: 14716738
[TBL] [Abstract][Full Text] [Related]
20. Androgen stimulates matrix metalloproteinase-2 expression in human prostate cancer.
Liao X; Thrasher JB; Pelling J; Holzbeierlein J; Sang QX; Li B
Endocrinology; 2003 May; 144(5):1656-63. PubMed ID: 12697668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
